sponsored
PatientsVille.com Logo

PatientsVille

Danatrol Medical Research Studies

Up-to-date List of Danatrol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Danatrol Medical Research Studies

Rank Status Study
1 Unknown  Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
Conditions: Fanconi Anemia;   Dyskeratosis Congenita
Intervention: Drug: danazol
Outcome Measures: Toxicity associated with danazol therapy: virilization, and/or new or progressive evidence of either hepatic or renal toxicity at a Grade II level using National Cancer Institute Common Toxicity Criteria (NCI-CTC).;   The optimal dose and hematologic response rate in Fanconi anemia (FA) and Dyskeratosis congenita (DC) patients receiving danazol therapy;   The gene expression profile of progenitor cells in response to danazol, both to predict responsiveness and to screen for small molecules that show a profile similar to that of responsive patients
2 Recruiting Danazol Treatment in Endometriosis Women Before IVF
Conditions: Endometriosis;   Ovarian Cysts;   Infertility
Interventions: Drug: Danazol;   Drug: placebo
Outcome Measures: pregnancy rate;   implantation rate
3 Recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Best overall response rate as determined by International Working Group criteria;   Survival time;   Adverse event rate(s), assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4)
4 Recruiting Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Drug: Danazol
Outcome Measures: To assess the total number of plasma exchanges performed within 30 days of initiation of the first plasma exchange.;   Time to Remission
5 Recruiting Danazol for Genetic Bone Marrow and Lung Disorders
Condition: Aplastic Anemia
Intervention: Drug: Danazol
Outcome Measures: Toxicity profile in the 24 months following danazol therapy. The biologic endpoint is reduction in telomere attrition rate yearly.;   a) hematologic response;   b) relapse;   c) clonal evolution;   d) myelodysplasia or acute leukemia;   e) survival;   f) progression of PETs and CT scans;   g) 6-minute walk test
6 Recruiting A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: Low Dose Danazol;   Drug: Placebo
Outcome Measure: Improvement in Best Corrected Visual Acuity
7 Unknown  Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)
Condition: Thrombocytopenia
Intervention: Other: Steroid refractory ITP
Outcome Measures: Proportion who would avoid splenectomy at 6 months of follow up;   SR,IR
8 Recruiting A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura
Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Outcome Measures: the subject incidence and exposure adjusted incidence of adverse events, including clinically significant changes in laboratory values and incidence of antibody formation.;   Platelet response to romiplostim defined as platelet counts 50x109/L in the absence of rescue medication.;   The prevalence of concurrent ITP therapy use over time (corticosteroids, danazol, azathioprine, etc.).
9 Unknown  Progestin Treatment for Endometrial Stromal Cells in Adenomyosis
Condition: Endometriosis
Intervention:
Outcome Measure:
10 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
Outcome Measures: Efficacy;   Symptomatic Efficacy
11 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
Outcome Measure: Efficacy

These studies may lead to new treatments and are adding insight into Danatrol etiology and treatment.

A major focus of Danatrol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Danatrol